Literature DB >> 28503332

Chronic Neuropsychological Sequelae in a Patient with Nontumorous Anti-NMDA-Receptor Encephalitis.

Dong Y Han1,2,3, Lisa M Koehl1, Aarti Patel4, Zhengqiu Zhou1, Sarah Phillips1, Siddharth Kapoor1.   

Abstract

Anti-N-methyl-D-aspartate receptor encephalitis is a neurological, autoimmune disorder tightly conceptualized only as recently as the mid-2000s. It presents itself in a combination of psychiatric, neurological, and autonomic features. We observe a unique case with probable earlier episode (prior to the mid-2000s conceptualization of the disease) and a later relapse, accompanying a comprehensive neuropsychological profile tracked after the relapse and subsequent improvement. Neurocognitive findings revealed residual frontal deficits with mood changes even in the state after plasmapheresis. This case is the first to describe posttreatment cognition in anti-NMDAR encephalitis after probable serial autoimmune episodes.

Entities:  

Year:  2017        PMID: 28503332      PMCID: PMC5414487          DOI: 10.1155/2017/5675732

Source DB:  PubMed          Journal:  Case Rep Neurol Med        ISSN: 2090-6676


1. Introduction

Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a neurological, autoimmune disorder that presents itself in a combination of psychiatric, neurological, and autonomic features. Typical representations include generally acute personality and behavioral changes, memory loss, hallucinations, dyskinesia, dystonia, and seizures. Significant portions of the patients, up to 80%, are women with a median age in the early twenties, and ovarian teratomas and related autoimmune processes are found in approximately half of the cases [1-5]. In this case report, we present a patient with two paroxysms of anti-NMDAR encephalitis accompanied by limited cognitive abilities, frontal deficits, and mood changes.

2. Case Presentation

The patient is a 33-year-old married woman. She managed the financial aspects and business ventures of the three companies that she and her husband own. Her social history was reported normal with no incidents of significant trauma or substance abuse. Developmental history is unremarkable, and she completed one and a half years of college. The family history showed bipolar disorder in one sibling, hypertension, diabetes, and a strong presence of depression. Upon records review, documentation revealed that the patient possibly, or rather probably, experienced her first episode of autoimmune encephalitis at the age of 24, which occurred prior to the first conceptualization documented by Dalmau et al. [3]. This episode was paired with headaches, hallucinations, delusions, violent outbursts, seizures, and then a two-month long coma. During this time, hallucinations included seeing a television on the ceiling. She was hospitalized at an inpatient psychiatric facility, but details of her clinical diagnoses at the time remain unclear. She then recovered drastically after receiving a high dose of prednisone and only reported mild to moderate residual deficits. While no formal neuropsychological measures were given at the time per report, residual deficits included low-level math computation, slowed processing speed, and short-term memory deficits, enough to a level that required supervision over daily living activities. This continued to resolve for about 2 years until she was able to drive and care for her children independently. However, she remained agitated and irritable compared to her baseline. The second episode occurred nine years later and was much more severe. It involved personality changes, perseveration in behaviors and speech, impulsive financial behaviors (e.g., spending over $10,000 on clothes in one week), paranoia, psychosis, and aggressive outbursts. She also had dressing apraxia, and her psychosis included visual hallucinations of monsters and demons, melting ceilings, delusions of her children being trapped under the bathroom tiles, and the belief that she had to free them using only her fingernails. She was under restraint during her inpatient stay for a week due to aggressive outbursts. She also developed status epilepticus 4 times, which were treated with conventional IV antiepileptic drugs. Video EEG showed epileptic activity in the right frontoparietal region. The remainder of the workup was negative, including MRI, CT, PET, transvaginal US, and LP. MRIs of the brain and pelvis were both negative (pelvic MRI was initiated to rule out ovarian teratoma). CSF was unrevealing including T. pallidum, West Nile, IgG, albumin, cell ct/protein/glucose, cultures, cryptococcal Ag, India ink, HSV PCR, and TB. Laboratory testing by Mayo Clinic revealed that the serum anti-NMDA antibodies were negative, but CSF anti-NMDA antibodies with repeat testing were found to be positive. Treatment included bilateral salpingo-oophorectomy (but no ovarian teratoma was found), IVIG transfusion, and plasmapheresis. She was later switched to rituximab infusion and also received medications for psychosis and seizures. Final diagnosis was documented as anti-NMDA-receptor encephalitis without teratoma. A neuropsychological evaluation occurred after treatment. It showed numerous cognitive deficits such as impairments in visual memory, mental flexibility, expressive language, visuospatial skills, and motor dexterity (see Table 1). The most significant problems were present in verbal fluency (semantic and phonemic fluency, both <1st percentile), mental flexibility (<1st percentile), and elevated depression and anxiety. She continues to have compromised cognitive status along with residual frontal deficits and mood changes. She and her guardian provided consent for this case study to be published.
Table 1

Neuropsychological test scores.

DomainFunctionMeasureStandard scoresPercentile
Expected intelligenceEstimated premorbid IQWRAT-4 Reading subtest8618

General intelligenceFull scale IQWAIS- IV755

Verbal memoryTotal verbal learningCVLT-II trials 1–5 total9845
New learning as distraction to old learningCVLT-II trial B10768
Short delay recallCVLT-II short delay787
Long delay recallCVLT-II long delay8516
RecognitionCVLT-II discriminability11584

Visual memoryTotal visual learningBVMT-R trials 1–3 total<65<1
Delay recallBVMT-R delay<65<1
RecognitionBVMT-R Discrimination Index1-2

AttentionWorking memoryWAIS-IV Working Memory Index809
Psychomotor speed & attentionTrails A8821

Higher order executive skillsMental flexibilityTrails B58.3
Response inhibitionStroop C-W9127
Novel problem solvingWCST total error787
WCST-64 perseverative responses8618
WCST-64 perseverative errors879
WCST-64 categories completed2–5
WCST-64 failure to maintain set

SpeedProcessing speedWAIS-IV Processing Speed Index8618
Recognition speedStroop W8414
Stroop C8616

Verbal generalVerbal comprehensionWAIS-IV Verbal Comprehension Index8313

ExpressiveSemantic fluencyAnimals58.3
Phonemic fluencyFAS58.3
NamingBNT-264.8
RepetitionMAE sentences713

ReceptiveComprehensionMAE token10667

General perceptionPerceptual reasoningWAIS-IV Perceptual Reasoning Index713

Visuospatial constructionVisuomotor constructionClock drawing

Spatial perceptionVisual perceptionJOLO798

MotorManual dexterityGD dominant hand671.4
GD nondominant hand64.8

WRAT-4 Reading = Wide Range Achievement Test, 4th Edition; WAIS-IV = Wechsler Adult Intelligence Scale, 4th Edition; CVLT-II = California Verbal Learning Test, 2nd Edition; BVMT-R = Brief Visuospatial Memory Test-Revised; Trails A = Trail Making Test Form A; Trails B = Trail Making Test Form B; Stroop C = Stroop Color Subtest; Stroop W = Stroop Word Subtest; Stroop C-W = Stroop Color-Word Subtest; WCST = Wisconsin Card Sorting Test; Animals = semantic fluency; FAS = phonemic fluency; BNT-2 = Boston Naming Test, 2nd Edition; MAE = Multilingual Aphasia Examination; JOLO = Judgment of Line Orientation Test; GD = grip dynamometer.

3. Discussion

In anti-NMDAR encephalitis, antibodies are directed towards the NR1 subunit of the NMDA receptor causing a depletion of NMDA receptors [1, 4, 6, 7]. The lack of receptors causes neuropsychiatric symptoms, attributable to ovarian teratomas and autoimmune processes in approximately half of the cases [2–4, 6, 8]. Recognizing the symptom complex is crucial to diagnosis [7]. Commonly, patients develop a multistage illness that progresses from psychiatric symptoms to more extreme global symptoms [1]. Up to half of the women diagnosed with anti-NMDAR encephalitis have an underlying ovarian teratoma [3, 8]. Treatment involves immunosuppression with steroids and intravenous administration [1, 4, 7, 9]. Many patients recover well after appropriate treatment [10]. While it is thought that there is a higher prevalence of anti-NMDAR encephalitis, data on posttreatment cognitive states remain rather limited [11, 12]. This case revealed residual frontal deficits with mood changes in the context of anti-NMDAR encephalitis. This case is the first to describe posttreatment cognition in anti-NMDAR encephalitis after probable serial autoimmune episodes.

4. Conclusion

Anti-N-methyl-D-aspartate receptor encephalitis is a neurological, autoimmune disorder tightly conceptualized only as recently as the mid-2000s. It presents itself in a combination of psychiatric, neurological, and autonomic features. This case was a unique case with probable earlier episode (prior to the mid-2000s operationalization of the disease) and a later relapse, accompanying a comprehensive neuropsychological profile tracked after the relapse and subsequent improvement. Neurocognitive findings revealed residual frontal deficits with mood changes even in the state after plasmapheresis, and these deficits do not appear to associate neatly with structural brain damage visible in imaging (or lack thereof), as clinical symptoms were likely the sequelae of a more global neuroinflammatory damage that occurred. This case is the first to describe posttreatment cognition in anti-NMDAR encephalitis after probable serial autoimmune episodes.
  12 in total

1.  Cognitive deficits following anti-NMDA receptor encephalitis.

Authors:  Carsten Finke; Ute A Kopp; Harald Prüss; Josep Dalmau; Klaus-Peter Wandinger; Christoph J Ploner
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-09-20       Impact factor: 10.154

Review 2.  [Contributions of neuropsychology to anti-NMDA receptor antibody encephalitis: a literature review].

Authors:  P Luna-Lario; P Hernaez-Goni; J Tirapu-Ustarroz
Journal:  Rev Neurol       Date:  2016-05-01       Impact factor: 0.870

Review 3.  Clinical characteristics, treatments, and outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis: A systematic review of reported cases.

Authors:  Le Zhang; Meng-Qian Wu; Zi-Long Hao; Siew Mun Vance Chiang; Kun Shuang; Min-Tao Lin; Xiao-Sa Chi; Jia-Jia Fang; Dong Zhou; Jin-Mei Li
Journal:  Epilepsy Behav       Date:  2017-01-19       Impact factor: 2.937

Review 4.  Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.

Authors:  Josep Dalmau; Eric Lancaster; Eugenia Martinez-Hernandez; Myrna R Rosenfeld; Rita Balice-Gordon
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

Review 5.  Neurology issues in schizophrenia.

Authors:  Katharina Hüfner; Beatrice Frajo-Apor; Alex Hofer
Journal:  Curr Psychiatry Rep       Date:  2015-05       Impact factor: 5.285

6.  Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.

Authors:  Josep Dalmau; Amy J Gleichman; Ethan G Hughes; Jeffrey E Rossi; Xiaoyu Peng; Meizan Lai; Scott K Dessain; Myrna R Rosenfeld; Rita Balice-Gordon; David R Lynch
Journal:  Lancet Neurol       Date:  2008-10-11       Impact factor: 44.182

Review 7.  Biological Perspectives: Anti-NMDA Receptor Encephalitis.

Authors:  Jonathan S Dowben; Peter C Kowalski; Norman L Keltner
Journal:  Perspect Psychiatr Care       Date:  2015-07-29       Impact factor: 2.186

Review 8.  Efficacies of treatments for anti-NMDA receptor encephalitis.

Authors:  Hsiuying Wang
Journal:  Front Biosci (Landmark Ed)       Date:  2016-01-01

Review 9.  Anti-N-methyl-d-aspartate receptor encephalitis: review of clinical presentation, diagnosis and treatment.

Authors:  Helen Barry; Susan Byrne; Elizabeth Barrett; Kieran C Murphy; David R Cotter
Journal:  BJPsych Bull       Date:  2015-02

Review 10.  Paraneoplastic neurological syndromes associated with ovarian tumors.

Authors:  Mikolaj Piotr Zaborowski; Marek Spaczynski; Ewa Nowak-Markwitz; Slawomir Michalak
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-26       Impact factor: 4.553

View more
  1 in total

1.  A case of reversible anti-NMDA-receptor encephalitis: neuropsychological and neuroradiological features.

Authors:  Carlotta Mutti; Federica Barocco; Lucia Zinno; Anna Negrotti; Marco Spallazzi; Giovanni Pavesi; Simona Gardini; Paolo Caffarra
Journal:  Neurol Sci       Date:  2017-09-13       Impact factor: 3.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.